| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
12,650,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Exagen is engaged in commercializing a portfolio of testing products under its AVISE® brand, several of which are based on its Cell-Bound Complement Activation Products (CB-CAPs) technology. CB-CAPs assess the activation of the complement system, a biological pathway that is implicated across various autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE). Co.'s main testing product, AVISE® CTD, enables diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs), and other related diseases with overlapping symptoms. AVISE® CTD utilizes Co.'s CB-CAPs technology to enable the diagnosis SLE.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
40,401 |
40,401 |
40,401 |
130,401 |
| Total Buy Value |
$77,570 |
$77,570 |
$77,570 |
$318,770 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
2 |
| Total Shares Sold |
0 |
19,522 |
53,341 |
72,317 |
| Total Sell Value |
$0 |
$37,540 |
$96,558 |
$136,333 |
| Total People Sold |
0 |
1 |
2 |
3 |
| Total Sell Transactions |
0 |
2 |
3 |
7 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tullis James L L |
Director |
– • – |
2021-08-05 |
4 |
AS |
$10.72 |
$72,863 |
I/I |
(6,800) |
1,515,672 |
|
- |
|
| Tullis James L L |
Director |
– • – |
2021-08-04 |
4 |
AS |
$11.39 |
$23,917 |
I/I |
(2,100) |
1,522,472 |
|
- |
|
| Tullis James L L |
Director |
– • – |
2021-08-03 |
4 |
AS |
$11.77 |
$50,618 |
I/I |
(4,300) |
1,524,572 |
|
- |
|
| Tullis James L L |
Director |
– • – |
2021-08-02 |
4 |
AS |
$11.92 |
$21,454 |
I/I |
(1,800) |
1,528,872 |
|
- |
|
| Tullis James L L |
Director |
– • – |
2021-06-29 |
4 |
AS |
$14.67 |
$78,910 |
I/I |
(5,379) |
1,530,672 |
|
- |
|
| Tullis James L L |
Director |
– • – |
2021-06-28 |
4 |
AS |
$14.98 |
$162,696 |
I/I |
(10,858) |
1,536,051 |
|
- |
|
| Tullis James L L |
Director |
– • – |
2021-06-25 |
4 |
AS |
$16.03 |
$140,503 |
I/I |
(8,763) |
1,546,909 |
|
- |
|
| Hazeltine Mark |
Chief Operating Officer |
• – – |
2021-05-17 |
4 |
OE |
$0.26 |
$503 |
D/D |
1,934 |
39,434 |
|
- |
|
| Hazeltine Mark |
Chief Operating OfficerOfficer |
• – – |
2021-03-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
37,500 |
|
- |
|
| Adawi Kamal |
Chief Financial Officer |
• – – |
2021-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
37,500 |
|
- |
|
| Rocca Fortunato R. |
President and CEO |
• • – |
2021-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
| Zack Debra |
Chief Medical Officer |
• – – |
2021-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
37,500 |
|
- |
|
| Tullis James L L |
Director |
– • • |
2021-02-05 |
4 |
AS |
$17.00 |
$51,000 |
D/D |
(3,000) |
21,348 |
|
- |
|
| Hunt Woody L |
10% Owner |
– – • |
2021-01-25 |
4 |
S |
$16.01 |
$448,616 |
I/I |
(28,021) |
1,261,324 |
|
- |
|
| Hunt Woody L |
10% Owner |
– – • |
2021-01-22 |
4 |
S |
$16.07 |
$379,991 |
I/I |
(23,646) |
1,289,345 |
|
- |
|
| Hunt Woody L |
10% Owner |
– – • |
2021-01-21 |
4 |
S |
$16.01 |
$800,700 |
I/I |
(50,000) |
1,312,991 |
|
- |
|
| Hunt Woody L |
10% Owner |
– – • |
2021-01-20 |
4 |
S |
$16.13 |
$483,990 |
I/I |
(30,000) |
1,362,991 |
|
- |
|
| Hunt Woody L |
10% Owner |
– – • |
2021-01-19 |
4 |
S |
$16.00 |
$480,048 |
I/I |
(30,000) |
1,392,991 |
|
- |
|
| Tullis James L L |
Director |
– • • |
2021-01-19 |
4 |
AS |
$15.56 |
$3,998 |
D/D |
(257) |
24,348 |
|
- |
|
| Tullis James L L |
Director |
– • • |
2021-01-15 |
4 |
AS |
$15.51 |
$15,725 |
D/D |
(1,014) |
24,605 |
|
- |
|
| Tullis James L L |
Director |
– • • |
2021-01-13 |
4 |
AS |
$15.58 |
$89,534 |
D/D |
(5,729) |
25,619 |
|
- |
|
| Hunt Woody L |
10% Owner |
– – • |
2021-01-12 |
4 |
S |
$16.04 |
$240,584 |
I/I |
(15,000) |
1,422,991 |
|
- |
|
| Hunt Woody L |
10% Owner |
– – • |
2021-01-11 |
4 |
S |
$16.03 |
$118,526 |
I/I |
(7,394) |
1,437,991 |
|
- |
|
| Hunt Woody L |
10% Owner |
– – • |
2021-01-08 |
4 |
S |
$16.07 |
$244,039 |
I/I |
(15,186) |
1,445,385 |
|
- |
|
| Hunt Woody L |
10% Owner |
– – • |
2021-01-07 |
4 |
S |
$16.04 |
$160,400 |
I/I |
(10,000) |
1,460,571 |
|
- |
|
104 Records found
|
|
Page 2 of 5 |
|
|
